244
Participants
Start Date
June 9, 2014
Primary Completion Date
July 5, 2022
Study Completion Date
July 5, 2022
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Ruxolitinib
Oral inhibitor of JAK kinase
Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Erasmus University Medical Center, Rotterdam
University Medical Center Groningen, Groningen
Stony Brook Medicine, Stony Brook
Institut Paoli-Calmettes, Marseille
Charité - Universitätsmedizin Berlin, Berlin
Georgetown University - Lombardi Cancer Center, Washington D.C.
University Vita-Salute San Raffaele, Milan
Universitätsklinik Hamburg-Eppendorf, Hamburg
University of Maryland, Baltimore
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
Emory University, Atlanta
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
Moffitt Cancer Center, Tampa
CHRU de Tours - Hôpital Bretonneau, Tours
Vanderbilt-Ingram Cancer Center, Nashville
Policlinico Sant'Orsola Malpighi, Bologna
Centre Hospitalier Universitaire de Nantes, Nantes
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
Unità Operativa di Ematologia Ospedale Santa Maria delle Croci, Ravenna
Medical College of Wisconsin, Milwaukee
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz
Loyola University Chicago - Cardinal Bernadin Cancer Center, Maywood
Washington University School of Medicine, St Louis
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola
The University of Texas MD Anderson Cancer Center, Houston
III. Med. Klinik-Klinikum rechts der Isar-Technische Universität München, Munich
City of Hope National Medical Center, Duarte
UCSD Moores Cancer Center, La Jolla
UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco
University of California, San Francisco, San Francisco
Medizinische Klinik und II, Universitätsklinikum Würzburg, Würzbur
Providence Portland Medical Center, Portland
Fred Hutchinson Cancer Research Center, Seattle
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
Universitätsklinikum Leipzig, Leipzig
Rambam Health Care Campus, Haifa
Shaare Zedek Medical Center, Jerusalem
Universitat Autonomaa de Barcelona (UAB) - Hospital de la Santa Creu i de Sant Pau, Barcelona
Hospital Universitario 12 de Octubre, Madrid
King's Health Partners, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
MacroGenics
INDUSTRY